UNIGE document Scientific Article
previous document  unige:95090  next document
add to browser collection
Title

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

Authors
Gauthier, Serge
Feldman, Howard H
Schneider, Lon S
Wilcock, Gordon K
Hardlund, Jiri H
Moebius, Hans J
Bentham, Peter
show hidden authors show all authors [1 - 18]
Published in The Lancet. 2016, vol. 388, no. 10062, p. 2873-2884
Abstract Leuco-methylthioninium bis(hydromethanesulfonate; LMTM), a stable reduced form of the methylthioninium moiety, acts as a selective inhibitor of tau protein aggregation both in vitro and in transgenic mouse models. Methylthioninium chloride has previously shown potential efficacy as monotherapy in patients with Alzheimer's disease. We aimed to determine whether LMTM was safe and effective in modifying disease progression in patients with mild to moderate Alzheimer's disease.
Identifiers
PMID: 27863809
Full text
Article (Published version) (422 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Structures
Research group Troubles de mémoire et maladie d'Alzeimer (935)
Citation
(ISO format)
GAUTHIER, Serge et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. In: The Lancet, 2016, vol. 388, n° 10062, p. 2873-2884. https://archive-ouverte.unige.ch/unige:95090

8 hits

0 download

Update

Deposited on : 2017-06-27

Export document
Format :
Citation style :